← FDA DRUG APPROVALS

FDA BLA · BLA103293

PROLEUKIN

aldesleukin

Sponsor: CHIRON

APPLICATION
BLA103293
TYPE
BLA
ORIGINAL APPROVAL
1992-05-05
LATEST ACTION
2023-09-29
ROUTE
INTRAVENOUS
DOSAGE FORM
VIAL
MARKETING STATUS
Prescription

Products

PROLEUKINPrescription
ALDESLEUKIN 22MIU/VIAL · VIAL

Approval history

2023-09-29Labeling · Supplement 5154 · standardLabelAP
2019-05-17Labeling · Supplement 5146 · standardLetterAP
2015-05-06Labeling · Supplement 5139 · standardAP
2012-07-30Labeling · Supplement 5130 · standardLabelAP
2011-12-16Labeling · Supplement 5123 · standardLetterAP
2011-07-19Labeling · Supplement 5114 · standardLetterAP
2010-07-06Labeling · Supplement 5099 · standardAP
2010-03-17Labeling · Supplement 5088 · standardAP
2009-04-08Labeling · Supplement 5087 · standardAP
2000-06-27Labeling · Supplement 1029 · standardAP
1998-01-09Efficacy · Supplement 1019 · unknownAP
1998-01-09Efficacy · Supplement 1021 · priorityReviewAP
1992-05-05Type 1 - New Molecular Entity · Original · unknownAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →